home / stock / glaxf / glaxf news


GLAXF News and Press, GlaxoSmithKline Plc From 05/11/20

Stock Information

Company Name: GlaxoSmithKline Plc
Stock Symbol: GLAXF
Market: OTC
Website: gsk.com

Menu

GLAXF GLAXF Quote GLAXF Short GLAXF News GLAXF Articles GLAXF Message Board
Get GLAXF Alerts

News, Short Squeeze, Breakout and More Instantly...

GLAXF - ADC Therapeutics Cuts Price In 2nd IPO Attempt

Quick Take ADC Therapeutics ( ADCT ) intends to raise $125 million from the sale of its common stock, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors. ADCT is making a new attempt to go pu...

GLAXF - Gilead: Strategic Update - Focus On 'Defend/Extend' HIV Franchise

Background This is Part 2 of a 2-part set of articles about Gilead ( GILD ); Part 1 focused on its remdesivir ("RDV") for COVID-19. There is probably more going on at GILD than the focus on RDV in GILD's recent Q1 earnings report and conference call could allow to be discussed. The ...

GLAXF - 5%+ Dividend Yield Portfolio: Bracing For The Retest (April 2020 Review)

Musings Unless you are solely invested in Technology stocks, your portfolio is likely nothing but a sea of red this year (despite a bump off the lows in April). Basically everything is hurting (no shocker there), but that’s not what I’m focused on at the moment. I’m tryi...

GLAXF - GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q1 2020 Results - Earnings Call Transcript

GlaxoSmithKline plc (GSK) Q1 2020 Results Conference Call April 29, 2020 09:00 AM ET Company Participants Sarah Elton-Farr - Head, IR Emma Walmsley - CEO Luke Miels - President, Global Pharmaceuticals Iain Mackay - CFO Hal Barron - Chief Scientific Officer and President, R&am...

GLAXF - GlaxoSmithKline plc 2020 Q1 - Results - Earnings Call Presentation

The following slide deck was published by GlaxoSmithKline plc in conjunction with their 2020 Q1 earnings Read more ...

GLAXF - Tonix Trial Update, And Other News: The Good, Bad And Ugly Of Biopharma

Tonix Goes Ahead with Late Stage Fibromyalgia Tonix Pharmaceuticals Holding Corp. ( TNXP ) announced that it has hit 50 percent enrollment milestone for its Phase 3 RELIEF trial. The trial will incorporate a pivotal study of TNX-102 SL 5.6 mg for managing fibromyalgia. The drug candidate ...

GLAXF - Biotech Melt-Up

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...

GLAXF - 5%+ Dividend Yield Portfolio: Buying When Things Go On Sale (Mar 2020 Review)

Musings Shorter update this month since life is too crazy to look backwards at the moment, plus I made a ton of trades to report (so no gory graphs demonstrating the pain I am sure that your portfolio dashboard is telling you). I don’t believe that any of the posted numbers (espec...

GLAXF - GlaxoSmithKline's Nucala Success, And Other News: The Good, Bad And Ugly Of Biopharma

GlaxoSmithKline's Nucala Achieves Co-Primary Endpoints GlaxoSmithKline ( GSK ) announced that its drug candidate Nucala met co-primary endpoints for the pivotal SYNAPSE study. The trial was designed to assess the efficacy of this asthma drug in treating patients with nasal polyps associa...

GLAXF - Color Ultrasonic Diagnostic Apparatus Market To Witness Steady Growth through 2029

New York City, NY:March 27, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Color Ultrasonic Diagnostic Apparatus Market in Global Industry: 2020 Research and New Innovations in Medical Devices Sector. The prime objective of the report is to ...

Previous 10 Next 10